The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Periodontitis drugs.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Periodontitis drugs is a notable innovation area in the pharmaceutical industry
Periodontal diseases, which may lead to the damage of teeth or bone, are caused by infections and inflammation of the gums and bone that surround and support the teeth. Symptoms of these diseases include bleeding, swollen and red gums. The drugs used in the treatment of periodontal diseases are corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), antiseptics, and antibiotics.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 40+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of periodontitis drugs.
Key players in periodontitis drugs – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to periodontitis drugs
Source: GlobalData Patent Analytics
Revance Therapeutics is one of the leading patent filers of periodontitis drugs. Revance Therapeutics is a biotechnology company that focuses on the development, manufacturing, and marketing of novel botulinum toxin products. The company works towards improving patient and physician experiences through the development, acquisition and commercialisation of innovative aesthetic and therapeutic offerings.
In terms of application diversity, Credentis (acquired by vVardis) is the top company, followed by Kitasato Daiichi Sankyo Vaccine and Sideromics. By means of geographic reach, BioGaia holds the top position. Revance Therapeutics and Bio Minerals are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.